Netherlands | Biotechnology, Healthcare & Startups
Information checked on 7 October 2026.
RougeTx has launched with $58 million in Series A financing to advance an experimental treatment for hereditary haemorrhagic telangiectasia (HHT), an inherited disorder that causes abnormal blood vessels and recurrent bleeding.
The Naarden-based biotechnology company announced the funding on 6 October 2026. Its lead programme, RTX-001, is being developed as a potential once-daily oral medicine intended to improve blood vessel stability.
RTX-001 remains at the preclinical stage. The financing will support its progress towards first-in-human development, with safety and benefit in patients still to be established.
The company’s approach centres on pericytes, cells that help support small blood vessels. RougeTx aims to turn research into how these cells function into treatments that address the vascular instability associated with HHT.
Who Is Backing the RougeTx Funding Round?
The Series A was co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners. Other participants included Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures.
The European Investment Bank participated through the Aurea co-investment vehicle alongside Angelini Ventures.
Angelini describes the transaction as its first investment in the Netherlands. Its investment announcement highlights both RTX-001 and the possibility of applying RougeTx’s research to other diseases involving unstable blood vessels.
From a business perspective, the financing supports two connected objectives: advancing a lead drug candidate and developing further programmes around the same area of biology.
The value of that strategy will depend on whether the company can generate convincing clinical evidence while building a research pipeline with distinct, testable opportunities.
What Is Hereditary Haemorrhagic Telangiectasia?
HHT affects how blood vessels develop. It can cause abnormal connections between arteries and veins, known as arteriovenous malformations, that bypass the usual network of small vessels called capillaries.
Smaller vascular abnormalities, called telangiectasias, can occur in areas such as the nose, mouth, skin and digestive tract. Fragile vessels can bleed repeatedly.
Frequent nosebleeds and gastrointestinal bleeding are important features of the disease. Repeated blood loss can lead to iron deficiency and anaemia. Vascular malformations involving organs such as the lungs, liver and brain can cause additional complications.
The condition varies between people, including within families. The location of the affected vessels and the severity of bleeding influence its impact.
This variation matters for drug development. A study needs to define which patients it includes and which aspects of the disease it intends to improve.
Why Better HHT Treatments Are Needed
RougeTx says there are currently no medicines approved specifically for HHT. Existing care nevertheless provides ways to manage bleeding, address iron deficiency and treat particular vascular malformations.
Depending on the patient’s needs, care can include iron replacement, procedures for troublesome nosebleeds and interventions to close abnormal blood vessel connections. Some medicines approved for other conditions are also used off-label.
A new drug would need to demonstrate a useful benefit within this existing care landscape.
Reducing the burden of repeated bleeding could be meaningful for patients. Establishing that benefit requires more than showing an effect in a laboratory: researchers need to assess symptoms, treatment needs, safety and daily functioning in people living with the disease.
How RTX-001 Is Designed to Work
Pericytes sit around small blood vessels and interact with endothelial cells, which form the vessels’ inner lining. These interactions help vessels develop, mature and remain stable.
RougeTx is studying how disrupted communication and attachment between these cells contribute to fragile vessels.
According to the company, RTX-001 is designed to restore pericyte attachment and improve these supporting interactions. The intended result is greater vascular stability.
RougeTx describes this as a disease-modifying approach: an attempt to influence the biological process contributing to disease. That description expresses the programme’s goal, which still requires clinical validation.
The public launch announcement does not identify RTX-001’s specific molecular target. It also does not present human trial results.
Its potential once-daily oral format is a development objective. The eventual dosing schedule and suitability for long-term use will depend on the evidence generated during development.
The Academic Research Behind RougeTx
RougeTx is a spin-off from Leiden University Medical Center (LUMC).
The research organisation reNEW identifies Franck Lebrin and Jérémy Thalgott among its co-founders. Lebrin’s work on vascular biology spans more than two decades, beginning at Inserm and continuing at LUMC.
reNEW says it supported preclinical evaluation of RTX-001 using stem cell-based model systems. It also describes an academic research foundation combining pericyte biology, HHT models and advanced imaging.
These tools can help researchers investigate disease processes and observe how experimental compounds affect them. Their relevance to patients must subsequently be tested in clinical studies.
For RougeTx, the academic foundation provides a starting point for drug discovery. The next challenge is translating that research into a medicine with a reproducible effect and an acceptable safety profile.
What the Financing Could Support in Clinical Development
In an interview with BioXconomy, chief executive Andrew Lightfoot said the financing is expected to support evaluation of RTX-001 in a double-blind, placebo-controlled Phase IIa study involving people with HHT.
That is a stated development ambition. RougeTx’s launch announcement describes the company as preclinical and positions the immediate programme towards first-in-human development.
Early clinical studies generally investigate safety, dosing and how a drug behaves in the body. Later studies examine whether it produces a meaningful benefit in the intended patient population.
The launch announcement does not provide a trial start date or planned patient numbers.
As the programme progresses, the study design will matter alongside the results. Patient selection, treatment duration, comparison groups and the measures used to assess improvement will determine what conclusions can reasonably be drawn.
How the periSCOPE Platform Could Expand the Pipeline
RougeTx’s periSCOPE platform is intended to support the development of additional small-molecule therapies for diseases involving pericyte dysfunction and vascular instability.
The company describes an integrated relationship with LUMC and other collaborators. Its initial focus is HHT, with an ambition to apply the underlying research more broadly.
For a biotechnology startup, that approach could create further development opportunities around a shared scientific foundation.
Each additional programme would still need its own evidence. A biological mechanism that matters in one disease does not establish that a particular drug will work in another.
The strength of periSCOPE will therefore become clearer as RougeTx identifies further candidates, explains their intended uses and publishes supporting results.
RougeTx Enters an Active HHT Research Field
Other companies already have HHT programmes in clinical development.
Cure HHT’s September 2026 research updates list Vaderis’s Phase III HEROIC study and Atavistik Bio’s Phase I/II Harmony-HHT study.
HEROIC is evaluating a daily oral capsule, including its effects on nosebleed frequency and severity, quality of life, safety and tolerability. Harmony-HHT is studying an investigational treatment in people with HHT.
These programmes show that the search for better treatment involves several approaches at different stages.
For RougeTx, the opportunity is to establish what its focus on vessel-supporting cells can contribute. Comparisons between programmes will require careful attention to differences in trial populations, study designs and outcomes.
What Will Matter in RougeTx’s Next Phase?
The next milestones will concern both clinical readiness and the quality of the evidence produced.
| Question | Evidence that would help answer it |
|---|---|
| Can RTX-001 be used safely? | Clinical findings on side effects, tolerability and dose |
| Does it improve outcomes for patients? | Controlled results showing a meaningful effect on the symptoms studied |
| Can any benefit be sustained? | Follow-up assessing treatment effects and safety over time |
| Can the platform support further medicines? | Clearly defined candidates with supporting disease-specific research |
These are measures for assessing future progress, rather than results established by the financing announcement.
RougeTx now has funding to advance its research towards clinical testing. For people living with HHT, the significance of that investment will ultimately depend on whether the programme can produce a safe, effective and practical treatment.
Explore more global business, technology and innovation coverage in The Empire Magazine’s article archive.
Read our related healthcare innovation coverage: ghost-core-ai-computer-11-million-funding/
Follow The Empire Magazine:
Facebook | Instagram
The Empire Magazine | Crown For Global Insights
